Abbott Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q1 results met expectations with 3.7% sales growth and $1.15 adjusted EPS, despite higher financing costs and a weak respiratory season. The Exact Sciences acquisition is integrating well, driving growth in cancer diagnostics, while medical devices and pharma segments delivered strong performances.
Fiscal Year 2025
-
Delivered double-digit EPS growth and margin expansion in 2025, with strong performance in medical devices and diagnostics offsetting near-term nutrition headwinds. 2026 guidance targets 10% EPS growth and 7% organic sales growth, supported by innovation, new product launches, and the Exact Sciences acquisition.
-
Abbott will acquire Exact Sciences for $21B to expand into advanced cancer diagnostics, doubling its diagnostics market and creating a new growth platform. The deal is expected to close in Q2 2026, with synergies focused on revenue growth and international expansion.
-
Organic sales grew 7.5% year-over-year, led by double-digit growth in medical devices and strong international performance. Adjusted EPS rose to $1.30, and the company remains confident in sustaining high single-digit sales and double-digit EPS growth into 2026, supported by innovation and new product launches.
-
Delivered high single-digit sales growth, margin expansion, and double-digit EPS growth in Q2, driven by strong performance in medical devices and emerging markets, despite headwinds in diagnostics and tariffs. Guidance reaffirmed for high single-digit sales and double-digit EPS growth.
-
Q1 2025 delivered high single-digit sales and double-digit EPS growth, with strong margin expansion and robust performance across most segments. Tariff impacts are expected in the second half but are being actively mitigated, and full-year guidance is reaffirmed.
Fiscal Year 2024
-
Delivered 10% Q4 sales growth (excluding COVID testing) and 13% EPS growth, with strong performance across all segments. 2025 guidance calls for 7.5%-8.5% organic sales growth and double-digit EPS growth, supported by margin expansion and robust product pipelines.
-
Organic sales grew over 8% year-over-year, led by strong MedTech and Diabetes Care results, while Nutrition and Diagnostics faced temporary challenges. Guidance for full-year revenue and EPS was reiterated, with robust product launches, strategic partnerships, and a new $7B buyback program supporting momentum into 2025.
-
Organic sales growth exceeded 9% year-over-year (ex-COVID), with double-digit gains in medical devices and strong performance across all segments. Adjusted EPS rose 16% sequentially, prompting raised full-year guidance for both sales and earnings.